JP2010505832A5 - - Google Patents

Download PDF

Info

Publication number
JP2010505832A5
JP2010505832A5 JP2009531423A JP2009531423A JP2010505832A5 JP 2010505832 A5 JP2010505832 A5 JP 2010505832A5 JP 2009531423 A JP2009531423 A JP 2009531423A JP 2009531423 A JP2009531423 A JP 2009531423A JP 2010505832 A5 JP2010505832 A5 JP 2010505832A5
Authority
JP
Japan
Prior art keywords
phenyl
methyl
piperazin
pyrazol
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009531423A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010505832A (ja
JP5346292B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/021182 external-priority patent/WO2008042388A1/en
Publication of JP2010505832A publication Critical patent/JP2010505832A/ja
Publication of JP2010505832A5 publication Critical patent/JP2010505832A5/ja
Application granted granted Critical
Publication of JP5346292B2 publication Critical patent/JP5346292B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009531423A 2006-10-03 2007-10-02 5−ht2aセロトニン受容体に関連する障害の処置に有用な5−ht2aセロトニン受容体の調整因子としてのピラゾール誘導体 Expired - Fee Related JP5346292B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84907006P 2006-10-03 2006-10-03
US60/849,070 2006-10-03
PCT/US2007/021182 WO2008042388A1 (en) 2006-10-03 2007-10-02 Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013141517A Division JP2013199493A (ja) 2006-10-03 2013-07-05 5−ht2aセロトニン受容体に関連する障害の処置に有用な5−ht2aセロトニン受容体の調整因子としてのピラゾール誘導体

Publications (3)

Publication Number Publication Date
JP2010505832A JP2010505832A (ja) 2010-02-25
JP2010505832A5 true JP2010505832A5 (enExample) 2010-11-18
JP5346292B2 JP5346292B2 (ja) 2013-11-20

Family

ID=38926423

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009531423A Expired - Fee Related JP5346292B2 (ja) 2006-10-03 2007-10-02 5−ht2aセロトニン受容体に関連する障害の処置に有用な5−ht2aセロトニン受容体の調整因子としてのピラゾール誘導体
JP2013141517A Withdrawn JP2013199493A (ja) 2006-10-03 2013-07-05 5−ht2aセロトニン受容体に関連する障害の処置に有用な5−ht2aセロトニン受容体の調整因子としてのピラゾール誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013141517A Withdrawn JP2013199493A (ja) 2006-10-03 2013-07-05 5−ht2aセロトニン受容体に関連する障害の処置に有用な5−ht2aセロトニン受容体の調整因子としてのピラゾール誘導体

Country Status (14)

Country Link
US (6) US9434692B2 (enExample)
EP (1) EP2066641B1 (enExample)
JP (2) JP5346292B2 (enExample)
CN (2) CN102838546B (enExample)
AR (1) AR063100A1 (enExample)
AU (1) AU2007305235C1 (enExample)
CA (1) CA2664398C (enExample)
CL (1) CL2007002859A1 (enExample)
ES (1) ES2494846T3 (enExample)
JO (1) JO2954B1 (enExample)
PA (1) PA8749401A1 (enExample)
PE (1) PE20081454A1 (enExample)
TW (1) TWI415845B (enExample)
WO (1) WO2008042388A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4198733B2 (ja) * 2003-07-22 2008-12-17 アリーナ ファーマシューティカルズ, インコーポレイテッド 関連性障害の予防および処置に有用な、5−ht2aセロトニンレセプターのモジュレーターとしてのジアリールおよびアリールへテロアリールウレア誘導体
SA05260357B1 (ar) 2004-11-19 2008-09-08 ارينا فارماسيتو تيكالز ، أنك مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به
AU2007254244C1 (en) 2006-05-18 2014-07-31 Arena Pharmaceuticals, Inc. 3-pyrazolyl-benzamide-4-ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
JP5406018B2 (ja) 2006-05-18 2014-02-05 アリーナ ファーマシューティカルズ, インコーポレイテッド 5−ht2aセロトニンレセプターに関連する障害の処置に有用な5−ht2aセロトニンレセプターのモジュレーターとしての1級アミン、およびその誘導体
NZ571829A (en) 2006-05-18 2011-10-28 Arena Pharm Inc Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor
TWI415845B (zh) * 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與5-ht2a血清素受體相關聯病症之作為5-ht2a血清素受體之調節劑的吡唑衍生物
WO2008054748A2 (en) * 2006-10-31 2008-05-08 Arena Pharmaceuticals, Inc. Indazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
US9567327B2 (en) 2007-08-15 2017-02-14 Arena Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
DE102007047737A1 (de) * 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) * 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
CN102264354B (zh) 2008-10-28 2015-03-25 艾尼纳制药公司 用于治疗5-ht2a5-羟色胺受体相关障碍的5-ht2a5-羟色胺受体调节剂组合物
WO2011075596A1 (en) 2009-12-18 2011-06-23 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
LT3575792T (lt) * 2011-05-31 2023-03-10 Biogen Ma Inc. Pdl rizikos vertinimo būdas
US10022263B2 (en) 2011-07-14 2018-07-17 Cook Medical Technologies Llc Sling-based treatment of obstructive sleep apnea
WO2014189540A1 (en) 2012-10-16 2014-11-27 Catalano Peter J Method and apparatus for treating obstructive sleep apnea (osa)
CA2919504A1 (en) 2013-08-01 2015-02-05 Christine BRONIKOWSKI Tissue adjustment implant
JP6364078B2 (ja) 2013-08-05 2018-07-25 クック・メディカル・テクノロジーズ・リミテッド・ライアビリティ・カンパニーCook Medical Technologies Llc 解放可能なチューブ状部材を有する医療機器およびその使用方法
EP2898920B1 (en) 2014-01-24 2018-06-06 Cook Medical Technologies LLC Articulating balloon catheter
US9974563B2 (en) 2014-05-28 2018-05-22 Cook Medical Technologies Llc Medical devices having a releasable member and methods of using the same
US9913661B2 (en) 2014-08-04 2018-03-13 Cook Medical Technologies Llc Medical devices having a releasable tubular member and methods of using the same
WO2016051226A1 (en) * 2014-09-29 2016-04-07 Hitachi, Ltd. Management system for computer system
WO2016201373A1 (en) * 2015-06-12 2016-12-15 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
HK1247555A1 (zh) 2015-07-15 2018-09-28 Axovant Sciences Gmbh 用於预防和治疗与神经变性疾病相关的幻觉的作为5-ht2a血清素受体的调节剂的二芳基脲和芳基杂芳基脲衍生物
EP3263567A1 (en) * 2016-07-01 2018-01-03 AiCuris Anti-infective Cures GmbH Carboxamide-substituted pyrazoles and tri(hetero)aryl-pyrazoles for use in methods of treating and / or preventing cardiovascular diseases and / or comorbidities thereof
JP6650852B2 (ja) * 2016-09-14 2020-02-19 マルハニチロ株式会社 ドコサヘキサエン酸を含有する睡眠の質改善剤
CN110430875A (zh) * 2017-01-13 2019-11-08 大日本住友制药株式会社 用于与帕金森病相关的非运动症状的治疗剂
CN111093572A (zh) 2017-06-29 2020-05-01 库克医学技术有限责任公司 用于重新定位组织的可植入医疗装置
EP3684463B1 (en) 2017-09-19 2025-05-14 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US11318277B2 (en) 2017-12-31 2022-05-03 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US12280219B2 (en) 2017-12-31 2025-04-22 NeuroLight, Inc. Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
US11452839B2 (en) 2018-09-14 2022-09-27 Neuroenhancement Lab, LLC System and method of improving sleep
DK3947360T3 (da) 2019-03-28 2024-08-26 Zoetis Services Llc Serotonin 5-HT2B-hæmmende forbindelser
US20220354831A1 (en) * 2021-05-04 2022-11-10 Mind Medicine, Inc. Movement disorders

Family Cites Families (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US654472A (en) * 1900-02-03 1900-07-24 George A Mayer Hub-attaching device.
DE1643310A1 (de) 1966-12-29 1971-06-03 Dow Chemical Co 4-Alkyl-2,5-dimethoxy-alpha-methyl-phenaethylamin und seine pharmakologisch vertraeglichen Salze
US4099012A (en) * 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
DE2926517A1 (de) * 1979-06-30 1981-01-15 Beiersdorf Ag Substituierte 3-aryl-pyrazole und 5-aryl-isoxazole und verfahren zu ihrer herstellung
DE2928485A1 (de) * 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
IL61721A (en) 1980-12-16 1984-03-30 Blank Izhak Nitroglycerin preparations
US4555399A (en) 1983-11-18 1985-11-26 Key Pharmaceuticals, Inc. Aspirin tablet
US4985352A (en) * 1988-02-29 1991-01-15 The Trustees Of Columbia University In The City Of New York DNA encoding serotonin 1C (5HT1c) receptor, isolated 5HT1c receptor, mammalian cells expressing same and uses thereof
IT1227626B (it) 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
EP0412798A3 (en) 1989-08-08 1992-07-01 Merck Sharp & Dohme Ltd. Substituted pyridines, their preparation, formulations and use in dementia
US5661024A (en) * 1989-10-31 1997-08-26 Synaptic Pharmaceutical Corporation DNA encoding a human serotonic (5-HT2) receptor and uses thereof
US5077409A (en) * 1990-05-04 1991-12-31 American Cyanamid Company Method of preparing bis-aryl amide and urea antagonists of platelet activating factor
US5128351A (en) * 1990-05-04 1992-07-07 American Cyanamid Company Bis-aryl amide and urea antagonists of platelet activating factor
JPH04334357A (ja) 1991-05-02 1992-11-20 Fujirebio Inc 酵素阻害作用を有するアシル誘導体
FR2682379B1 (fr) * 1991-10-09 1994-02-11 Rhone Poulenc Agrochimie Nouveaux phenylpyrazoles fongicides.
FR2690440B1 (fr) * 1992-04-27 1995-05-19 Rhone Poulenc Agrochimie Arylpyrazoles fongicides.
DE69411176T2 (de) * 1993-08-20 1998-11-12 Smithkline Beecham Plc Amide und harnstoffderivate als 5ht1d rezeptor antagonisten
FR2722369B1 (fr) 1994-07-13 1998-07-10 Rhone Poulenc Agrochimie Compositions fongicides a base de derives 3-phenyl-pyrazoles pour le traitement du materiel vegetal de multiplication, nouveaux derives 3-phenyl-pyrazoles et leurs applications fongicides
CA2200981A1 (en) 1994-10-04 1996-04-11 Hisashi Takasugi Urea derivatives and their use as acat-inhibitors
CA2135253A1 (en) 1994-11-07 1996-05-08 Michael Dennis Compound screening based on a window of chemical-messenger-independent activity
CA2212061A1 (en) * 1995-02-02 1996-08-08 Laramie Mary Gaster Indole derivatives as 5-ht receptor antagonist
US6540981B2 (en) 1997-12-04 2003-04-01 Amersham Health As Light imaging contrast agents
WO1996025157A1 (en) * 1995-02-17 1996-08-22 Smithkline Beecham Corporation Il-8 receptor antagonists
US5856326A (en) 1995-03-29 1999-01-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
ES2149471T3 (es) 1995-04-20 2000-11-01 Eurand Int Compuesto con glicolato de almidon sodico como material soporte y productos a base de dicho compuesto.
US5861431A (en) 1995-06-07 1999-01-19 Iotek, Inc. Incontinence treatment
AU6526896A (en) 1995-07-22 1997-02-18 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US6005008A (en) * 1996-02-16 1999-12-21 Smithkline Beecham Corporation IL-8 receptor antagonists
GB9607219D0 (en) * 1996-04-04 1996-06-12 Smithkline Beecham Plc Novel compounds
JP2000510862A (ja) 1996-05-24 2000-08-22 ニューロサーチ・アクティーゼルスカブ クロライドチャンネル遮断剤として有用なフエニル誘導体
CA2255858C (en) * 1996-05-24 2007-09-11 Neurosearch A/S Phenyl derivatives containing an acidic group, their preparation and their use as chloride channel blockers
BR9709938A (pt) * 1996-06-27 1999-08-10 Smithkline Beecham Corp Antagonistas dos receptores de il-8
WO1998000016A1 (en) 1996-07-01 1998-01-08 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
US6063808A (en) 1996-07-01 2000-05-16 Sepracor Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (S,S)-glycopyrrolate
CA2269707C (en) 1996-10-25 2005-08-16 Edward M. Rudnic Soluble form osmotic dose delivery system
JP2001508767A (ja) 1996-12-02 2001-07-03 藤沢薬品工業株式会社 5―ht拮抗作用を有するインドール―ウレア誘導体
US6420541B1 (en) * 1998-04-14 2002-07-16 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6541209B1 (en) * 1997-04-14 2003-04-01 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6696475B2 (en) * 1997-04-22 2004-02-24 Neurosearch A/S Substituted phenyl derivatives, their preparation and use
RU2197482C2 (ru) * 1997-04-22 2003-01-27 НьюроСёрч А/С Замещенные фенильные производные, способ их получения, содержащая их фармацевтическая композиция и способ лечения (варианты)
US6028083A (en) * 1997-07-25 2000-02-22 Hoechst Marion Roussel, Inc. Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
CA2294064A1 (en) 1997-07-29 1999-02-11 Smithkline Beecham Corporation Il-8 receptor antagonists
WO1999009988A1 (en) 1997-08-27 1999-03-04 Hexal Ag New pharmaceutical compositions of meloxicam with improved solubility and bioavailability
CN1327443A (zh) * 1997-10-31 2001-12-19 艾文蒂斯药品有限公司 取代的酰苯胺化合物
JPH11183942A (ja) 1997-12-19 1999-07-09 Nippon Mitsubishi Oil Corp エレクトロクロミック素子
EP1042305B1 (en) 1997-12-22 2005-06-08 Bayer Pharmaceuticals Corp. INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS
US7517880B2 (en) * 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
DE1049664T1 (de) 1997-12-22 2001-05-03 Bayer Corp., Pittsburgh Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen
AU764766B2 (en) 1998-04-14 2003-08-28 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6140509A (en) * 1998-06-26 2000-10-31 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
GB9816263D0 (en) * 1998-07-24 1998-09-23 Merck Sharp & Dohme Therapeutic agents
US6358698B1 (en) * 1998-10-07 2002-03-19 Acadia Pharmacueticals Inc. Methods of identifying inverse agonists of the serotonin 2A receptor
EE04849B1 (et) * 1998-10-22 2007-06-15 Neurosearch A/S Asendatud fenüülderivaadid, nende valmistamine jakasutamine
US6150393A (en) * 1998-12-18 2000-11-21 Arena Pharmaceuticals, Inc. Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors
US6180138B1 (en) 1999-01-29 2001-01-30 Abbott Laboratories Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
RU2001129155A (ru) 1999-03-26 2003-08-10 Еро-Сельтик С.А. (Lu) Соединения с арильными заместителями (варианты), фармацевтическая композиция и способ лечения расстройства, чувствительного к блокаде натриевых каналов у млекопитающего, способ лечения, профилактики различных заболеваний или уменьшения интенсивности гибели или потери нейронов (варианты), способ облегчения или предупреждения эпилептических припадков у животного (варианты), соединение - радиоактивный лиганд для участка связывания в натриевом канале
GB9909409D0 (en) 1999-04-24 1999-06-23 Zeneca Ltd Chemical compounds
US6469006B1 (en) * 1999-06-15 2002-10-22 Bristol-Myers Squibb Company Antiviral indoleoxoacetyl piperazine derivatives
IT1312115B1 (it) 1999-06-24 2002-04-04 Nicox Sa Composti amorfi e relative composizioni farmaceutiche
HUP0203375A3 (en) 1999-07-28 2005-03-29 Aventis Pharm Prod Inc Substituted oxoazaheterocyclyl compounds
US6541477B2 (en) 1999-08-27 2003-04-01 Scios, Inc. Inhibitors of p38-a kinase
WO2001021160A2 (en) 1999-09-23 2001-03-29 Axxima Pharmaceuticals Aktiengesellschaft Carboxymide and aniline derivatives as selective inhibitors of pathogens
US6531291B1 (en) * 1999-11-10 2003-03-11 The Trustees Of Columbia University In The City Of New York Antimicrobial activity of gemfibrozil and related compounds and derivatives and metabolites thereof
EP1108720A1 (en) 1999-12-08 2001-06-20 Basf Aktiengesellschaft Herbicidal 2-Pyrazolyl-6-Aryloxy-Pyri(mi)dines
CA2395075A1 (en) 1999-12-16 2001-06-21 Miles P. Smith 1,3,4-substituted piperidine analogs and uses thereof in treating addictions
MXPA02006137A (es) 1999-12-20 2002-12-05 Neuromed Tech Inc Bloqueadores del canal de calcio parcialmente saturados.
WO2001064676A2 (en) 2000-02-28 2001-09-07 Scios, Inc. INHIBITORS OF p38-α KINASE
FR2810979B1 (fr) * 2000-06-29 2002-08-23 Adir Nouveaux derives de diphenyluree, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB0021885D0 (en) 2000-09-06 2000-10-18 Fujisawa Pharmaceutical Co New use
WO2002039987A2 (en) 2000-11-14 2002-05-23 Neurosearch A/S Use of malaria parasite anion channel blockers for treating malaria
AR035521A1 (es) 2000-12-22 2004-06-02 Lundbeck & Co As H Derivados de 3-indolina y composicion farmaceutica que los comprende
WO2002055496A1 (en) 2001-01-15 2002-07-18 Glaxo Group Limited Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
US20020156068A1 (en) 2001-03-22 2002-10-24 Behan Dominic P. Anti-psychosis combination
WO2003002097A1 (en) 2001-06-29 2003-01-09 Eurand Pharmaceuticals Ltd Process of thermodynamical activation of water-insoluble drugs loaded into cross-linked polymers
JP4733877B2 (ja) 2001-08-15 2011-07-27 富士通セミコンダクター株式会社 半導体装置
HRP20080382A2 (en) * 2001-09-21 2008-12-31 Bristol-Myers Squibb Company A Delaware (Usa) Corporation LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS
WO2003062206A2 (en) 2002-01-23 2003-07-31 Arena Pharmaceuticals, Inc. Small molecule modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
US6743864B2 (en) 2002-03-12 2004-06-01 Basell Poliolefine Italia S.P.A. Polyolefin compositions having high tenacity
WO2004034963A2 (en) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
WO2004028450A2 (en) 2002-09-24 2004-04-08 Arena Pharmaceuticals, Inc. Process of making phenylpyrazoles useful as selective 5ht2a modulators and intermediates thereof
US7635709B2 (en) 2002-09-26 2009-12-22 The United States Of America As Represented By The Department Of Veterans Affairs Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction
WO2004045118A2 (en) 2002-11-08 2004-05-27 Interdigital Technology Corporation Composite channel quality estimation techniques for wireless receivers
WO2004046110A1 (ja) 2002-11-15 2004-06-03 Yamanouchi Pharmaceutical Co., Ltd. メラニン凝集ホルモン受容体拮抗剤
US7247628B2 (en) * 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US20060229335A1 (en) * 2002-12-24 2006-10-12 Bradley Teegarden Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a
EP1594512A4 (en) 2003-02-11 2007-07-11 Kemia Inc COMPOUNDS FOR THE TREATMENT OF VIRUS INFECTIONS
MXPA05010496A (es) 2003-03-28 2005-11-16 Pharmacia & Upjohn Co Llc Moduladores alostericos positivos del receptor de acetilcolina nicotinico.
GB0309781D0 (en) 2003-04-29 2003-06-04 Glaxo Group Ltd Compounds
FR2855825B1 (fr) * 2003-06-04 2008-08-22 Aventis Pharma Sa Produits aryl-heteroaromatiques, compositions les contenant et utilisation
EP1695966A1 (en) 2003-07-22 2006-08-30 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
JP4198733B2 (ja) * 2003-07-22 2008-12-17 アリーナ ファーマシューティカルズ, インコーポレイテッド 関連性障害の予防および処置に有用な、5−ht2aセロトニンレセプターのモジュレーターとしてのジアリールおよびアリールへテロアリールウレア誘導体
EP1653960A4 (en) 2003-08-13 2008-11-26 Amgen Inc MELANIN CONCENTRATION HORMONE RECEPTOR ANTAGONIST
US7091236B1 (en) 2003-08-20 2006-08-15 Sciele Pharma, Inc. Method for increasing the bioavailability of glycopyrrolate
US20050054691A1 (en) * 2003-08-29 2005-03-10 St. Jude Children's Research Hospital Carboxylesterase inhibitors
AU2004268918A1 (en) 2003-09-03 2005-03-10 Galapagos Nv Imidazo(1,5-a)pyridine or imidazo(1,5-a)piperidine derivatives and their use for the preparation of medicament against 5-HT2A receptor-related disorders
DE10354604B4 (de) * 2003-11-21 2016-10-13 Gesellschaft für Aufladetechnik und Spindelbau mbH Stufenlos schaltbares, magnetodynamisches Getriebe
WO2005077345A1 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
EP1727803B3 (en) 2004-03-23 2014-04-23 Arena Pharmaceuticals, Inc. Processes for preparing substituted n-aryl-n'-[3-(1h-pyrazol-5-yl)phenyl] ureas and intermediates thereof
US20060014705A1 (en) * 2004-06-30 2006-01-19 Howitz Konrad T Compositions and methods for selectively activating human sirtuins
US20060172992A1 (en) 2004-08-13 2006-08-03 Eisai Co., Ltd. Therapeutic agent for overactive bladder resulting from cerebral infarction
EP1786422A2 (en) 2004-08-16 2007-05-23 Prosidion Limited Aryl urea derivatives for treating obesity
US20060063754A1 (en) * 2004-09-21 2006-03-23 Edgar Dale M Methods of treating a sleep disorder
US7846915B2 (en) * 2004-10-20 2010-12-07 Resverlogix Corporation Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
US20090239841A1 (en) 2004-10-27 2009-09-24 Hutchison Alan J Diaryl Ureas as CB1 Antagonists
WO2006049734A2 (en) 2004-10-29 2006-05-11 Hypnion, Inc. Quetiapine analogs and methods of use thereof
AU2005302452B2 (en) 2004-11-01 2010-12-09 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in Amyotrophic Lateral Sclerosis
SA05260357B1 (ar) 2004-11-19 2008-09-08 ارينا فارماسيتو تيكالز ، أنك مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به
GB0426313D0 (en) 2004-12-01 2005-01-05 Merck Sharp & Dohme Therapeutic agents
AR051978A1 (es) 2004-12-01 2007-02-21 Divergence Inc Composiciones plaguicidas y metodos
WO2006060762A2 (en) * 2004-12-03 2006-06-08 Arena Pharmaceuticals, Inc. Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
DE102004061593A1 (de) 2004-12-21 2006-06-22 Abbott Gmbh & Co. Kg Substituierte N-heterocyclische Verbindungen und ihre therapeutische Verwendung
EP1831172B1 (en) 2004-12-28 2009-02-18 Council of Scientific and Industrial Research Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors
US7625931B2 (en) 2005-01-14 2009-12-01 Cgi Pharmaceuticals, Inc. Certain substituted diphenyl ureas, as modulators of kinase activity
WO2006078610A1 (en) 2005-01-19 2006-07-27 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis or treatment of progressive multifocal leukoencephalopathy
CA2595483A1 (en) 2005-01-21 2006-07-27 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical formulations of zonisamide and methods for their manufacture
AR052886A1 (es) 2005-01-26 2007-04-11 Arena Pharm Inc Procedimientos para preparar fenilpirazol ureas sustituidas y para la obtencion de sus intermediarios de sintesis
MX2007009092A (es) 2005-01-27 2007-09-12 Janssen Pharmaceutica Nv Derivados de tetrahidrofurano tetraciclicos heterociclicos como inhibidores de 5ht2 en el tratamiento de trastornos del sistema nervioso central.
GT200600042A (es) 2005-02-10 2006-09-27 Aventis Pharma Inc Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a
WO2006089871A2 (en) 2005-02-23 2006-08-31 Neurosearch A/S Diphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias
GB0504828D0 (en) 2005-03-09 2005-04-13 Merck Sharp & Dohme Therapeutic agents
GB0505437D0 (en) 2005-03-17 2005-04-20 Merck Sharp & Dohme Therapeutic agents
GB0505725D0 (en) 2005-03-19 2005-04-27 Merck Sharp & Dohme Therapeutic agents
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
ES2340066T3 (es) 2005-04-26 2010-05-28 Hypnion, Inc. Compuestos de benzisoxazol piperidina y procedimiento de uso de los mismos.
EP1734039A1 (en) 2005-06-13 2006-12-20 Esbatech AG Aryl urea compounds as BETA-secretase inhibitors
US8569352B2 (en) 2005-06-27 2013-10-29 Exelixis Patent Company Llc Imidazole based LXR modulators
US7754724B2 (en) * 2005-06-30 2010-07-13 Dow Agrosciences Llc N-substituted piperazines
US8093401B2 (en) * 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7544685B2 (en) 2005-08-17 2009-06-09 H. Lundbeck A/S 2,3-dihydroindole compounds
TWI329641B (en) 2005-08-31 2010-09-01 Otsuka Pharma Co Ltd (benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same
EA200800971A1 (ru) 2005-09-29 2008-08-29 Арена Фармасьютикалз, Инк. Фармацевтические композиции модулятора 5-нтрецепторов серотонина, полезные в лечении связанных с ними нарушений
WO2007120600A2 (en) 2006-04-10 2007-10-25 Arena Pharmaceuticals, Inc. 3-pyridinyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
GB0608655D0 (en) 2006-05-03 2006-06-14 Merck Sharp & Dohme Therapeutic Treatment
AU2007254244C1 (en) * 2006-05-18 2014-07-31 Arena Pharmaceuticals, Inc. 3-pyrazolyl-benzamide-4-ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
JP2009537556A (ja) 2006-05-18 2009-10-29 アリーナ ファーマシューティカルズ, インコーポレイテッド 5−ht2aセロトニンレセプターに関連する障害の処置に有用な5−ht2aセロトニンレセプターのモジュレーターとしてのアセトアミド誘導体
JP5406018B2 (ja) 2006-05-18 2014-02-05 アリーナ ファーマシューティカルズ, インコーポレイテッド 5−ht2aセロトニンレセプターに関連する障害の処置に有用な5−ht2aセロトニンレセプターのモジュレーターとしての1級アミン、およびその誘導体
NZ571829A (en) 2006-05-18 2011-10-28 Arena Pharm Inc Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor
JP2010502618A (ja) 2006-08-31 2010-01-28 アリーナ ファーマシューティカルズ, インコーポレイテッド セロトニン5−ht2a受容体のモジュレータとしてのベンゾフラン誘導体
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與5-ht2a血清素受體相關聯病症之作為5-ht2a血清素受體之調節劑的吡唑衍生物
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
WO2008054748A2 (en) 2006-10-31 2008-05-08 Arena Pharmaceuticals, Inc. Indazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
US8969402B2 (en) 2006-11-15 2015-03-03 Steven A. Rich Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
US8097633B2 (en) 2006-11-15 2012-01-17 Rich Steven A Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium
US9034890B2 (en) 2006-11-15 2015-05-19 Steven A. Rich Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
CN101679297B (zh) * 2006-12-08 2012-01-11 埃克塞利希斯股份有限公司 Lxr和fxr调节剂
US9567327B2 (en) 2007-08-15 2017-02-14 Arena Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
CN102264354B (zh) 2008-10-28 2015-03-25 艾尼纳制药公司 用于治疗5-ht2a5-羟色胺受体相关障碍的5-ht2a5-羟色胺受体调节剂组合物
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
JOP20210047A1 (ar) 2012-10-25 2017-06-16 Otsuka Pharma Co Ltd عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه
US9446037B2 (en) 2012-11-27 2016-09-20 Acadia Pharmaceuticals Inc. Methods for the treatment of parkinson's disease psychosis using pimavanserin
KR101472682B1 (ko) 2013-07-23 2014-12-15 고려대학교 산학협력단 메타물질 제조 방법, 이에 의해 제조된 메타물질 구조 필름 및 이를 이용한 광학 이미징 시스템
HK1247555A1 (zh) 2015-07-15 2018-09-28 Axovant Sciences Gmbh 用於预防和治疗与神经变性疾病相关的幻觉的作为5-ht2a血清素受体的调节剂的二芳基脲和芳基杂芳基脲衍生物

Similar Documents

Publication Publication Date Title
JP2010505832A5 (enExample)
JP2005526723A5 (enExample)
RU2485114C2 (ru) Карбоксамидные соединения и их применение в качестве ингибиторов кальпаинов
RU2361860C2 (ru) Новые замещенные 3-сера-индолы
RU2326869C2 (ru) Производные пиридазин-3(2h)-она в качестве ингибиторов фосфодиэстеразы 4 (pde4), способ их получения, фармацевтическая композиция и способ лечения
JP2019537603A5 (enExample)
CA2829790C (en) Multisubstituted aromatic compounds as inhibitors of thrombin
JP2018530571A5 (enExample)
JP2012519179A5 (enExample)
JP2005538955A5 (enExample)
JP2009537543A5 (enExample)
JP2010533158A5 (enExample)
AU2018200736A1 (en) Multisubstituted aromatic compounds as serine protease inhibitors
RU2017121044A (ru) Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы
RU2015154987A (ru) Гетероциклические производные
JP2016519156A5 (enExample)
RU2013133800A (ru) Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний
CA2718383A1 (en) Heteroaryl-substituted dicyanopyridines and use thereof for treatment of cardiovascular diseases
EP1354603A1 (en) Concomitant drugs
JP2010505809A5 (enExample)
JP2012509936A5 (enExample)
JP2020500192A5 (enExample)
RU2012131276A (ru) Карбоксамидные соединения и их применение в качестве ингибиторов кальпаина
RU2019117958A (ru) Производные индола, полезные в качестве ингибиторов диацилглицерид-о-ацилтрансферазы 2
RU2013110324A (ru) Новые модуляторы trpv3